C. Fletcher

Gastroenterology · Journal of Clinical Oncology · 2000–2014

A researcher in the Science corpus: 22 papers; trusts 1 researcher and is trusted by 5 researchers here, as inferred from the citation graph.

Subfields

• Gastroenterology — 55 citations into it; #30 of 63 by trust here, #6 by citations

Whom C. Fletcher trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

1. M. Miettinen

Who trusts C. Fletcher overall

1. E. Ewing
2. Heikki Joensuu
3. Hodgkin Lymphoma
4. Z. Du
5. F. Mertens
6. G. Ottaviani

Papers from C. Fletcher's perspective

Ordered by how strongly the researchers C. Fletcher trusts endorse each paper. Same corpus, a different order for every researcher.

1. Diagnosis of gastrointestinal stromal tumors: A consensus approach. (Human Pathology)
2. KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors. (American Journal of Pathology)
3. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. (New England Journal of Medicine)
4. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Soft Tissue and Bone
5. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. (Journal of Clinical Oncology)
6. Structural Basis for the Autoinhibition and STI-571 Inhibition of c-Kit Tyrosine Kinase* (Journal of Biological Chemistry)
7. PDGFRA Activating Mutations in Gastrointestinal Stromal Tumors (Science)
8. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. (Annals of Surgery)
9. Nonparametric Estimation from Incomplete Observations
10. Biology of gastrointestinal stromal tumors. (Journal of Clinical Oncology)

Their papers

• BRAF mutations are sufficient to promote nevi formation and cooperate with p53 in the genesis of melanoma. (2005) — 692 citations
• WHO classification of soft tissue tumours: an update based on the 2013 (4th) edition (2014) — 894 citations
• The evolving classification of soft tissue tumours – an update based on the new 2013 WHO classification (2014) — 605 citations
• Nuclear expression of STAT6 distinguishes solitary fibrous tumor from histologic mimics (2014) — 717 citations
• PD-L1 Expression is Characteristic of a Subset of Aggressive B-Cell Lymphomas and Virus-Associated Malignancies (2013) — 789 citations
• WHO classification of tumours of soft tissue and bone (2013) — 3,712 citations
• Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. (2012) — 1,896 citations
• Diagnostic histopathology of tumors (2009) — 703 citations
• Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. (2008) — 728 citations
• Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. (2008) — 988 citations
• Inflammatory Myofibroblastic Tumor: Comparison of Clinicopathologic, Histologic, and Immunohistochemical Features Including ALK Expression in Atypical and Aggressive Cases (2007) — 934 citations
• NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines. (2007) — 660 citations
• Incidence patterns of soft tissue sarcomas, regardless of primary site, in the surveillance, epidemiology and end results program, 1978–2001: An analysis of 26,758 cases (2006) — 643 citations
• Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. (2006) — 805 citations
• tp53 mutant zebrafish develop malignant peripheral nerve sheath tumors. (2005) — 618 citations
• PDGFRA Activating Mutations in Gastrointestinal Stromal Tumors (2003) — 2,423 citations
• Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. (2003) — 2,287 citations
• Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. (2002) — 4,306 citations
• World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Soft Tissue and Bone (2002) — 4,545 citations
• Diagnosis of gastrointestinal stromal tumors: A consensus approach. (2002) — 3,676 citations